Skip to main content
LIFECOME BIOCHEMISTRY CO., LTD. logo

LIFECOME BIOCHEMISTRY CO., LTD. — Investor Relations & Filings

Ticker · 002868 ISIN · CNE100002QH2 LEI · 65560089EP03NANEN790 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,742 across all filing types
Latest filing 2025-06-27 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 002868

About LIFECOME BIOCHEMISTRY CO., LTD.

https://www.pclifecome.com

Lifecome Biochemistry Co., Ltd. focuses on the research, development, and large-scale production of fermentation-based veterinary pharmaceuticals and feed additives. The company’s core product portfolio includes Bacitracin Zinc, Bacitracin Methylene Disalicylate (BMD), and Colistin Sulfate, available in both active pharmaceutical ingredient (API) and premix forms. These biochemical products are primarily utilized in the livestock and poultry sectors to manage enteric health and improve feed efficiency. The organization operates advanced fermentation and purification facilities, maintaining compliance with international Good Manufacturing Practices (GMP) and various global regulatory standards. By leveraging specialized biotechnological processes, the company provides high-purity solutions aimed at enhancing animal nutrition and disease prevention across international markets.

Recent filings

Filing Released Lang Actions
绿康生化重大资产出售暨关联交易的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a major asset sale and related party transaction by a listed company, Green Kang Biochemical Co., Ltd. It includes extensive legal analysis, transaction details, approvals, contracts, and company background. The document references compliance with securities laws, stock exchange rules, and regulatory approvals. It is not a financial report, earnings release, or a simple announcement. It is a legal opinion specifically related to a major asset sale and restructuring transaction. This type of document fits best under the category of Legal Proceedings Report (LTR), as it deals with legal opinions on a significant corporate transaction and compliance with regulatory requirements.
2025-06-27 Chinese
绿康新能（上海）进出口贸易有限公司审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告及财务报表" which translates to "Audit Report and Financial Statements" for the years 2023 and 2024. It includes detailed financial statements such as balance sheets, income statements, cash flow statements, and statements of changes in equity, along with extensive notes on accounting policies and financial instruments. The presence of an auditor's opinion section, detailed financial data, and notes indicates this is a standalone audit report with financial statements, not a full annual report or just an announcement. The document length is substantial (15,000 characters), and it contains actual financial data and audit opinions, not merely a certification or announcement. Therefore, it fits the category of Audit Report / Information (AR). FY 2024
2025-06-27 Chinese
董事会关于本次交易符合《上市公司重大资产重组管理办法》第十一条规定的说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation by the board of directors of a company regarding a major asset restructuring transaction. It references compliance with the 'Measures for the Administration of Major Asset Restructuring of Listed Companies' (《上市公司重大资产重组管理办法》) and discusses the specifics of the transaction, including asset sales, compliance with laws, and governance structure. The content is focused on the transaction's compliance and rationale rather than announcing the transaction or providing financial results. This fits the category of a Capital/Financing Update (CAP), as it relates to a significant financing or capital structure change through asset sales. The document length is 1698 characters, which is sufficient for a detailed explanation but not a full financial report. Therefore, the classification is CAP with high confidence.
2025-06-27 Chinese
关于绿康生化股份有限公司本次重大资产重组前业绩异常或本次重组存在拟置出资产情形的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a specialized audit opinion report issued by an accounting firm (立信会计师事务所) regarding the company 绿康生化股份有限公司. It focuses on the verification of abnormal performance and asset disposition issues before a major asset restructuring. The report references audit reports for fiscal years 2022, 2023, and 2024, including unqualified opinions and special audit reports on non-operating funds and related party transactions. It details audit procedures and opinions on compliance with accounting standards, absence of false transactions, profit fabrication, related party benefits, and accounting policy changes. The document is a standalone audit-related report, not a full annual report or interim report, nor is it a brief announcement or certification. It fits the definition of an Audit Report / Information (AR) as it provides audit opinions, applied accounting principles, and results of special audit checks related to regulatory requirements for a major asset restructuring. The document length (5066 characters) supports it being a full report rather than a short announcement. Therefore, the classification is AR with high confidence. FY 2024
2025-06-27 Chinese
浙商证券股份有限公司关于本次交易相关主体不存在《上市公司监管指引第7号—上市公司重大资产重组相关股票异常交易监管》第十二条情形的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from an independent financial advisor (浙商证券股份有限公司) regarding the absence of certain regulatory violations related to a major asset restructuring transaction. It references a specific regulatory guideline (上市公司监管指引第7号) and confirms that no parties involved are under investigation or penalty for insider trading related to the transaction. The document is short (763 characters) and serves as a compliance or regulatory check rather than a full report or announcement of financial results. It does not contain financial statements or detailed financial data. This type of document fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2025-06-27 Chinese
绿康新能（上海）进出口贸易有限公司评估报告（银信评报字（2025）第C00094号）
Audit Report / Information Classification · 100% confidence The document is titled as an "资产评估报告" (Asset Evaluation Report) prepared according to Chinese asset evaluation standards. It is a detailed report assessing the market value of the entire equity of a subsidiary company (绿康新能（上海）进出口贸易有限公司) as of December 31, 2024. The report includes comprehensive sections such as the purpose of the evaluation, evaluation methods, assumptions, procedures, and detailed financial data. It is clearly an asset valuation report related to a proposed asset disposal by the parent company (绿康生化股份有限公司). This type of document is a standalone audit or valuation report, not a full annual or interim financial report, nor an announcement or presentation. It does not fit categories like Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Regulatory Filings (RNS). It is a specialized audit/valuation report. Therefore, the most appropriate classification is Audit Report / Information (AR). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification. FY 2024
2025-06-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.